Does tirzepatide reduce LV mass and paracardiac adipose tissue in patients with obesity-related HFpEF?
Patients with obesity-related heart failure with preserved ejection fraction (HFpEF)
Tirzepatide
Placebo
Change in LV mass and paracardiac adipose tissuesurrogate
In patients with obesity-related HFpEF, tirzepatide reduces LV mass and paracardiac adipose tissue, providing a potential physiologic mechanism for the clinical benefits seen in the main SUMMIT trial.
The CMR substudy of the SUMMIT trial demonstrated that tirzepatide therapy in obesity-related HFpEF led to reduced LV mass and paracardiac adipose tissue as compared with placebo, and the change in LV mass paralleled weight loss. These physiologic changes may contribute to the reduction in heart failure events seen in the main SUMMIT trial. (A Study of Tirzepatide LY3298176 in Participants With Heart Failure With Preserved Ejection Fraction HFpEF and Obesity: The SUMMIT Trial; NCT04847557).
Building similarity graph...
Analyzing shared references across papers
Loading...
Christopher M. Kramer
Barry A. Borlaug
Michael R Zile M
Journal of the American College of Cardiology
Mayo Clinic
University of Virginia
Cleveland Clinic
Building similarity graph...
Analyzing shared references across papers
Loading...
Kramer et al. (Mon,) studied this question.
www.synapsesocial.com/papers/6998c9c31658600b0203140c — DOI: https://doi.org/10.1016/j.jacc.2024.11.001